Digital Delivery of Living Well With COPD for Patient Education and Self-management - a Mixed-method Study

NCT ID: NCT07031440

Last Updated: 2025-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-31

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

COPD (Chronic Obstructive Pulmonary Disease) is a common lung disease. People suffering from COPD typically experience shortness of breath, coughing, and mucus production. The condition is usually treated with medication, but it is equally important that patients are well-informed about COPD and receive guidance on how to live with it.

The currently available program, "Living well with COPD (LWWCOPD)," is a patient education and self-management program offered on-site in healthcare institutions (such as the Lung League) over six sessions across six weeks. Studies have shown that participating in this program can improve quality of life and overall health, and COPD patients who have completed it tend to require hospitalization less frequently.

However, not all patients who could benefit from the program are able to attend in person-either due to the fixed schedule or because traveling to the training site is too difficult. Therefore, this study aims to determine whether the digital version of the "Living well with COPD" program is equally effective and perhaps more convenient for some patients. The digital version closely mirrors the existing program and consists of various modules that provide information about COPD and practical strategies for managing the disease in daily life. Only once its effectiveness is scientifically proven can the digital version be implemented in Switzerland for COPD patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

digital LWWCOPD

Group Type OTHER

digital LWWCOPD

Intervention Type BEHAVIORAL

LWWCOPD (Living well with COPD) contains six modules conventionally delivered by trained LWWCOPD Coaches. For the digital delivery the six modules are as closely adapted to the conventional LWWCOPD program as possible to make the two approaches comparable. Participants can access the digital LWWCOPD application by a weblink using a smartphone, tablet or desktop computer. Since the program duration of the conventional LWWCOPD is 6 weeks (one module per week), patients will be instructed to complete the digital LWWCOPD also within 6 weeks at their own pace, although completion within 12 weeks (3 months) is still possible. Modules can be repeated as chosen by the user. In contrast to the conventional delivery, the online delivery of LWWCOPD does not preview face-to-face contact between participants and healthcare providers, however if needed additional phone calls or meetings are still possible.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

digital LWWCOPD

LWWCOPD (Living well with COPD) contains six modules conventionally delivered by trained LWWCOPD Coaches. For the digital delivery the six modules are as closely adapted to the conventional LWWCOPD program as possible to make the two approaches comparable. Participants can access the digital LWWCOPD application by a weblink using a smartphone, tablet or desktop computer. Since the program duration of the conventional LWWCOPD is 6 weeks (one module per week), patients will be instructed to complete the digital LWWCOPD also within 6 weeks at their own pace, although completion within 12 weeks (3 months) is still possible. Modules can be repeated as chosen by the user. In contrast to the conventional delivery, the online delivery of LWWCOPD does not preview face-to-face contact between participants and healthcare providers, however if needed additional phone calls or meetings are still possible.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years
2. Diagnosis of COPD (any stage and severity)
3. Able to speak/read/understand German or French
4. Access to a cell phone, tablet or personal desktop computer with active internet access
5. Willing and able to understand and provide written informed consent
6. Current or recent enrolment in a pulmonary rehabilitation program is permitted

Exclusion Criteria

1. Inability to follow the procedures/instructions of the study or to participate in the intervention (e.g. due to language or cognitive barriers, psychological disorders, physical reasons)
2. Patients already having completed the conventional LWWCOPD
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cantonal Hospital St. Gallen, Switzerland

UNKNOWN

Sponsor Role collaborator

University Hospital, Geneva

OTHER

Sponsor Role collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STD0007385

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of COPD Co-Pilot
NCT02944591 UNKNOWN